Biotech · Public company · Ramsey, NJ, US
Adma Biologics, Inc.
Ticker ADMA · SEC CIK 0001368514
Track this companyFree. Adds Adma Biologics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials50 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline6
- Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]Phase 3 · Primary Immune Deficiency Disorders (PIDD)ClinicalTrials.gov · fetched Nov 12, 2026
- Hepatitis C Immune Globulin Intravenous (Human) 5%Phase 2 · Sequelae of Viral HepatitisClinicalTrials.gov · fetched Nov 12, 2026
- Asceniv™Primary Immune DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- BivigamHumoral Immune ResponseClinicalTrials.gov · fetched Nov 12, 2026
- BivigamPrimary Immune Deficiency DisorderClinicalTrials.gov · fetched Nov 12, 2026
- OtherPrimary Immune Deficiency DisorderClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)PHASE4 · UNKNOWN · started Sep 1, 2022ClinicalTrials.gov NCT05070455 · fetched Nov 12, 2026
- Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16PHASE4 · COMPLETED · started Dec 29, 2016ClinicalTrials.gov NCT03164967 · fetched Nov 12, 2026
- A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin ProductsUNKNOWN · started Dec 1, 2016ClinicalTrials.gov NCT03037359 · fetched Nov 12, 2026
- Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)PHASE3 · COMPLETED · started Sep 1, 2007ClinicalTrials.gov NCT00538915 · fetched Nov 12, 2026
- Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver TransplantationPHASE2 · TERMINATED · started May 1, 2007ClinicalTrials.gov NCT00473824 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 2, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 27, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 2, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 25, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Feb 25, 2026 · fetched Nov 12, 2026